Drug Trial Radar · NCT06024772
Multiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Jan 2027
Primary completion
Aug 1, 2027
Study completion Feb 2028
Sponsor
- Lead sponsor
- Thomas Jefferson UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Amsterdam UMC, location VUmc; Eindhoven University of Technology; Eigen; GE Healthcare; National Cancer Institute (NCI)
- First posted
- Sep 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn whether multiparametric ultrasound (mp-US) can detect clinically significant prostate cancer as effectively as multiparametric MRI (mp-MRI) in adult men undergoing prostate biopsy for suspected prostate cancer. The main questions it aims to answer are: Does mp-US-guided targeted biopsy detect clinically significant prostate cancer at a rate that is not inferior to mp-MRI-guided targeted biopsy? Can mp-US imaging collected at the time of biopsy be used to identify suspicious prostate lesions for targeted sampling? Researchers will compare mp-US-guided targeted biopsy plus systematic biopsy with mp-MRI-guided targeted biopsy plus systematic biopsy to see if mp-US achieves a similar detection rate for clinically significant prostate cancer. Participants will: Undergo mp-MRI within 30 days before prostate biopsy. Receive mp-US imaging at the time of biopsy. Undergo up to three mp-US-targeted biopsy cores of suspicious areas. Undergo up to three mp-MRI-targeted biopsy cores of suspicious areas. Receive a standard systematic prostate biopsy consisting of 12 biopsy cores.
Conditions
- Prostate Carcinoma
Interventions
ultiparametric Magnetic Resonance ImagingProcedure
Undergo mp-MRI
Perflutren lipid microsphereDrug
Given IV
Transrectal UltrasoundProcedure
Undergo transrectal mp-US
Biopsy of ProstateProcedure
Undergo prostate biopsies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Prostate cancer (PCa) detection rate of 3-dimensional (3D) multiparametric ultrasound (mp-US) combined with systematic biopsyTime frame: Up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.